PIK3CA and breast cancer: In the cohort without PIK3CA-mutated BC, there was no significant difference in the median PFS (7.4 months versus 5.6 months), suggesting that the PIK3CA gene may represent a predictive biomarker for alpelisib activity in this population (Andre et al., 2019[2]).